Brokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) PT at $88.29

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have been given a consensus recommendation of “Moderate Buy” by the twenty-two research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $88.3333.

A number of research firms recently issued reports on BMRN. Wedbush restated an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Wolfe Research reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th. Canaccord Genuity Group upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and upped their target price for the stock from $84.00 to $98.00 in a research note on Tuesday, January 20th. Stifel Nicolaus set a $68.00 target price on BioMarin Pharmaceutical in a report on Tuesday. Finally, Tudor Pickering set a $88.00 price target on BioMarin Pharmaceutical in a report on Monday, November 3rd.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $62.62 on Wednesday. BioMarin Pharmaceutical has a 52 week low of $50.76 and a 52 week high of $73.51. The business’s 50 day moving average price is $58.53 and its 200 day moving average price is $56.08. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. The firm has a market cap of $12.03 billion, a P/E ratio of 35.18, a P/E/G ratio of 0.68 and a beta of 0.26.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in BMRN. NewEdge Advisors LLC increased its holdings in BioMarin Pharmaceutical by 11.5% in the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 388 shares in the last quarter. Empowered Funds LLC grew its position in shares of BioMarin Pharmaceutical by 207.4% during the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock valued at $850,000 after acquiring an additional 8,112 shares during the period. Focus Partners Wealth increased its stake in shares of BioMarin Pharmaceutical by 70.2% in the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock valued at $835,000 after purchasing an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of BioMarin Pharmaceutical by 33.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 1,102 shares in the last quarter. Finally, New York State Teachers Retirement System raised its holdings in BioMarin Pharmaceutical by 1.1% in the 2nd quarter. New York State Teachers Retirement System now owns 107,605 shares of the biotechnology company’s stock worth $5,915,000 after purchasing an additional 1,167 shares during the period. 98.71% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Reported solid top-line growth: Q4 revenue rose ~17% YoY and full‑year 2025 revenue was up ~13% to $3.2B, driven by VOXZOGO and enzyme therapies; management also announced a definitive agreement to acquire Amicus, which would add marketed products (Galafold, Pombiliti + Opfolda) and diversify revenue. BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
• Positive Sentiment: Analysts remain constructive: TD Cowen maintained a Buy and a $120 PT citing the Amicus deal and multi‑year outlook; Bank of America reiterated Buy (PT $97) highlighting pipeline upside despite competitive headwinds. BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
• Neutral Sentiment: Management to present at multiple investor conferences in March (TD Cowen, Leerink, Jefferies, Barclays) — increases investor access but is informational rather than immediately value‑moving. BioMarin to Participate in Four Upcoming Investor Conferences in March
• Neutral Sentiment: Oppenheimer trimmed its price target slightly (from $98 to $95) but retained an Outperform rating — a modest signal that expectations were nudged lower but still above the stock’s current level. Benzinga
• Negative Sentiment: BioMarin said it will voluntarily withdraw Roctavian (hemophilia gene therapy) from the market — a material setback for the company’s gene‑therapy franchise and a key reason for near‑term share weakness. BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
• Negative Sentiment: Mixed/unclear earnings metrics: while revenue beat estimates, reported EPS and some GAAP figures were reported inconsistently across outlets and some headlines flagged an EPS miss — and guidance language (2026 guidance excluding Amicus) leaves near‑term visibility uncertain. BioMarin Q4 Earnings / Conference Call

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.